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Direct-To-Consumer Genetic Testing: Privacy
Issues & Impacts on Biological Relatives
Quinn Prchal*
ABSTRACT
Numerous direct-to-consumer genetic testing services now offer individuals genetic sequencing, testing, and ancestry mapping services outside of
the traditional healthcare infrastructure and regulatory barriers. The rise of
direct-to-consumer testing services presents policy questions on how to best
protect consumers while still promoting future innovation. From a data privacy perspective, concerns include who can share other people’s genetic information, what entities can use the information, what happens if the
information is stolen, and whether law enforcement, or other entities, can
request information from a third party. The overarching concern is that once
disclosed, genetic information often cannot be unshared or returned. Further,
genetic information from biological relatives can provide information on
others who have not personally disclosed or authorized disclosure of their
genetic information.
In the United States, a patchwork of regulations has been created at the
state level that exceeds the minimum requirements created by Congress. In
other parts of the world, countries and regional networks have similarly created varying regulations to govern genetic information and its use. This comment reviews various regulations both in the United States and Europe,
discusses the implications of the various regulatory schemes, and proposes a
regulatory regime. This proposal aims at harmonizing rules across jurisdictions, distinguishing between “faceless” and individually labeled data, and
seeks to allow for data use, testing, and development of new technology,
while limiting exposure of individuals genetic information.
I.

INTRODUCTION

Genetics has long been taught in schools, and over the last seventy years
has moved from the study of simple patterns of gene inheritance to one of the
five core concepts of biology.1 Previously, genetics was an academic discipline that studied the effect of genes within the body and how they impact
the body’s health, potential diseases, and physical expressions.2 Genetic testing in the clinical setting has long been increasing for both disease research
and family planning; however, with the direct-to-consumer options allowing
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1.

Michelle K. Smith & William B. Wood, Teaching Genetics: Past, Present, and
Future, 204 GENETICS 5, Aug. 30, 2016, at 5.

2.

See Genetics Basics, CDC, https://www.cdc.gov/genomics/about/basics.htm
[https://perma.cc/MV5W-NHE3].
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anyone to get gene testing, or search their ancestry, the frequency of genetic
testing has exploded.3 The increase in the availability and popularity of direct-to-consumer options means that the regulatory regime and impacts on
the industry are becoming more and more relevant to everyday life.4
With more scientific breakthroughs, the genetics industry has become
an increasingly popular area for study and innovation.5 In 2019, the industry
accounted for $12.6 billion in spending.6 It is expected to grow 10.1% every
year until 2027, when it is projected to be an over $21 billion industry.7 New
technology and innovation have provided numerous direct-to-consumer options for one to obtain gene testing.8 Some of the more popular direct-toconsumer companies include Ancestry.com and 23&Me.9 The industry is
growing as consumer offerings seek market share, with some companies
even bombarding consumers with television ads.10 These consumer offerings
do not appear to be disappearing anytime soon, and the majority of growth
favors consumer gene testing over, and rather than, medical gene testing.11
Interestingly, recent studies have found that Americans are increasingly worried about how private companies and the government use their private
data.12

3.

See Genetic Testing, Privacy, and Healthcare, AM. SOC’Y OF HUM. GENETICS
(Jan. 1, 2019), https://www.ashg.org/discover-genetics/testing-privacy/ [https://
perma.cc/9LGW-JC36]; see Smith & Wood, supra note 1, at 8–9.

4.

See AM. SOC’Y

5.

Sanjivan Gill & Onkar Sumant, Genetic Testing Market, ALLIED MKT. RSCH.
(Sept. 2020), https://www.alliedmarketresearch.com/genetic-testing-market
[https://perma.cc/2Y2J-V6KA].

6.

Id.

7.

Id.

8.

Eric Rosenbaum, 5 Biggest Risks of Sharing Your DNA with Consumer Genetic-Testing Companies, CNBC (June 16, 2018, 2:18 PM), https://
www.cnbc.com/2018/06/16/5-biggest-risks-of-sharing-dna-with-consumer-genetic-testing-companies.html [https://perma.cc/7KAR-FUKD].

9.

Id.

OF

HUM. GENETICS, supra note 3.

10. Peter Loftus, 23andMe Stops Genetic Test Marketing, WALL ST. J. (Dec. 2,
2013, 5:14 PM), https://www.wsj.com/articles/SB10001424052702304579
404579234503409624522 [https://perma.cc/4EZ6-ULW3].
11.

See id.

12. Brooke Auxier & Lee Rainie, Key Takeaways on Americans’ Views About Privacy, Surveillance, and Data-Sharing, PEW RSCH. CNTR. (Nov. 15, 2019),
https://www.pewresearch.org/fact-tank/2019/11/15/key-takeaways-on-americans-views-about-privacy-surveillance-and-data-sharing/ [https://perma.cc/
FPP7-ZT6R].
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With ever growing capabilities, genetics and gene analysis have an increasing ability to discern and impact our lives.13 Privacy issues in the genetics world touch on numerous issues including who is able to share the
information, what entities can use the information, what happens if the information is stolen, and whether law enforcement can request access to the information.14 Overall, the issue also presents a “pandora’s box” type concern
where once a person’s information is out in the open, it can never be “secret”
again.15 Furthermore, this issue is not limited to the United States.16 Globally,
individuals’ genetic data and personal information are exposed to the directto-consumer testing market.17
Tangentially, genetics is a unique field of study because genes are inherited and shared between familial relatives.18 Biological relations, or those of
close consanguineal lineage, sit in a precarious position of having many of
the same genes as their parents, siblings, and other family members.19 As the
world starts to regulate the genetics industry from a user perspective, there is
an extended privacy concern for those who could be impacted by the decisions of closely related individuals who choose to have genetic testing
done.20 Biologic familial matches in genes make identification of a close
match possible, and identification allows for a connection of the dots and the
possible illumination of information about individuals who have not taken a
genetic test.21
This comment will first discuss the background of the genetics industry
before delving into the privacy issues for both those being tested and those
related to them. Next, the comment will explore the current federal and state
regulations and some of the proposed regulations in the genomics field. It
will also consider the regulations in the European Union as well as some
individual European Union member states. To finish, the comment will dis13.

See generally J. Lyn Entrikin, Family Secrets and Relational Privacy: Protecting Not-So-Personal, Sensitive Information from Public Disclosure, 74 UNIV.
MIA. L. Rev. 781, 787 (2020).

14.

E.g., Rosenbaum, supra note 8.

15.

See Rob Stein, Easy DNA Identifications with Genealogy Databases Raise Privacy Concerns, NPR (Oct. 11, 2018, 3:58 PM), https://www.npr.org/sections/
health-shots/2018/10/11/656268742/easy-dna-identifications-with-genealogydatabases-raise-privacy-concerns [https://perma.cc/LJ8N-297X].

16.

See id.

17.

See Louiza Kalokairinou et al., Legislation of Direct-to-Consumer Genetic
Testing in Europe: A Fragmented Regulatory Landscape, 9 J. CMTY. GENETICS
117, 126 (2018).

18. Entrikin, supra note 13, at 888.
19.

Id.; see Stein, supra note 15.

20.

See Stein, supra note 15; Entrikin, supra note 13, at 888.

21.

See Stein, supra note 15; Entrikin, supra note 13, at 888.
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cuss the implications of the numerous regulations and provide a proposed
regulatory regime to protect the genetics industry, individual customers, and
unsuspecting third parties.
II.

BACKGROUND

The genetics industry and testing of genes has been a fixture of medical
work since the discovery of DNA by Watson and Crick in 1953.22 Most prior
discoveries were centered around the clinical and research-based work of
labs to discover the individual gene markers of cystic fibrosis and Huntington’s disease.23 The discovery of the polymerase chain reaction (PCR) process, which led to the discovery of the ordering sequence of DNA bases,
generated interest in the gene field in 1983.24 By the 1990s, the international
Human Genome Project culminated in sequencing the entire human genome
rather than just individual genes.25
Modern efforts in the medical field have somewhat shifted from simply
identifying markers for diseases to attempting to use genetics data and
knowledge to create medical treatments.26 The focus on treatment has included developments of vaccines.27 Additionally, testing genes related to certain diseases for preventative use has increased.28 This is seen in the work
testing genes such as the APOE gene or the BRCA gene, which have been
associated with Alzheimer’s disease and breast cancer, respectively.29 These
tests were traditionally completed in the medical setting, but new businesses
have emerged to serve the direct-to-consumer market.30 Offerings now range
from whole genome, partial genome, and ancestry testing options from companies, such as 23andMe, Ancestry.com DNA, and Family Tree DNA.31
Their capabilities span from a simple ancestry type of nationality crowdsourcing to more “serious” medical testing intended to identify risks or genetic disorders that in prior years was completed in a medical setting.32

22.

JORGE L. CONTRERAS & VIKRANT DESHMUKH, GENETICS, ETHICS
TION, ch. 13 at 2 (Susan Bourgey et al., eds., 2017).

23.

Id.

24.

Id.

25.

Id.

26.

Id. ch.13 at 3.

27.

Id.

28.

CONTRERAS & DESHMUKH, supra note 22, ch. 13 at 4–5.

29.

Id.

30.

CONTRERAS & DESHMUKH, supra note 22, ch. 13 at 6.

31.

Id. ch. 13 at 6–7.

32.

Id.

AND

EDUCA-
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Privacy issues confront these new genetic testing options on numerous
fronts.33 The most glaring issue is what a company is allowed to do with
genetic information once it is in the company’s possession.34 These companies are not bound by the HIPPA regulations that restrict most medical providers.35 First, given that regulation is being developed prospectively, there is
a question of whether the company can keep the information or in what scenarios retention is allowed.36 Retention of this information may give the company monetization opportunities.37 Recent examples show that some
companies use collected data internally and even provide the data to third
parties.38 Many companies include clauses in contracts that allow companies
to use the information as they see fit.39 A consumer may not consider it, but
there is chance their genetic information can be bought or sold.40 The further
the genetic information gets from the original collection source, the harder it
is to locate the information, control its use, and regulate the impacts on the
original subjects.41 Also, company policies and privacy statements are often
not set in stone, so depending on the company leadership and changing priorities, such as profitability or a change in strategy, a company could alter its
privacy policies.42 This means the company an individual trusted based on its
policies could shift in strategy at any point without needing an individual’s
consent.43 A company may be limited by law from providing or selling genetic information to other entities, but outright purchases of the entire testing
company that houses the genetic testing information, however, open an alternative avenue for third parties to acquire the information without it ever
“leaving” the initial company’s protective internal systems.44 These loopholes allow third party entities to obtain the data of direct-to-consumer testing providers or servicers through the purchase of the company, thereby

33. Rosenbaum, supra note 8.
34.

See Matthew Haag, FamilyTreeDNA Admits to Sharing Genetic Data With
F.B.I., N.Y. TIMES (Feb. 4, 2019), https://www.nytimes.com/2019/02/04/business/family-tree-dna-fbi.html [https://perma.cc/BE2W-X3NR].

35.

See id.

36.

See id.

37.

See id.

38.

Id.

39.

See id.

40. Rosenbaum, supra note 8.
41.

See id.

42.

See Haag, supra note 34.

43.

See id.

44. Rosenbaum, supra note 8.

358

SMU Science and Technology Law Review

[Vol. XXV

eliminating the third party designation and sidestepping regulations on transfer of information.45
A second issue involves hacking and the liability associated with genetic information being stolen.46 Information is never completely safe online,
and there is an increasing threat that genetic information can and will be
stolen.47 Without efforts to safeguard data this valuable information is potentially an easy target.48 An individual’s data may just be waiting for someone
to take advantage of a poorly defended servicer’s bank of genetic information.49 As more breakthroughs occur in the scientific arena, this information
will likely continue to increase in value, putting an even larger emphasis on
the risks of data breaches.50
Third, law enforcement has increasingly sought to solve crimes with the
DNA information contained in the databases of consumer testing companies.51 The rules of medical HIPPA protections do not bind direct-to-consumer companies to certain confidentiality rules normally associated with the
medical field.52 Law enforcement has seen success with this approach to get
around consent issues because some companies have been willing to share
information.53 This method has allowed law enforcement to obtain individuals’ DNA information from companies, while obtaining DNA test directly
from an individual normally requires direct consent or a court order.54 This
presents issues similar to the FBI asking for Apple’s help to open an iPhone,
but with genetic data at stake rather than electronic information.55 Moreover,
a phone may include encryption or other safety measures to protect personal
information, while a direct-to-consumer genetic testing company likely has
limited controls to internally protect an individual’s genetic data.56 The accessibility of information normally protected by court order presents a consti45.

See id.

46.

Id.

47.

See id.

48.

See id.

49.

See id.

50.

See Rosenbaum, supra note 8.

51. Haag, supra note 34.
52.

See id.

53.

See Entrikin, supra note 13, at 787.

54.

See generally id.

55. Russell Brandon, The FBI Has Asked Apple to Unlock Another Shooter’s
iPhone, THE VERGE (Jan. 7, 2020, 11:34 AM), https://www.theverge.com/
2020/1/7/21054836/fbi-iphone-unlock-apple-encryption-debate-pensacola-iossecurity [https://perma.cc/86NY-ABAU].
56.

See id.
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tutional issue, as the gateway to an individual’s data may be through a testing
company rather than the individual.57
Finally, there are implications for how genetic information can be used
in the insurance industry.58 At some level, this data could be used by actuaries in the health insurance, life insurance, and car insurance markets to triangulate risk factors associated with certain sets of genes.59 The problem with
that is those with recognizable risk factors could be forced to pay more or
less depending on the assessment by the insurance companies actuarial department.60 Though more of a policy issue, this involves some privacy concerns, as legislators will have to decide what information can be used by
insurance companies.61 As a policy question, the concept of risk sharing versus requiring individuals to pay for their enhanced risk factors likely has no
clear cut answer.62 However, it presents an interesting question hovering
around the insurance industry as to what information can be requested and
used to develop policies for customers.63 Overall, anyone participating in the
direct-to-consumer genetic testing market faces these numerous implications
and potential issues today.64
There are also impacts for the biological relatives of those who participate in genetic testing.65 Unlike a social security number, that if given away
would just impact oneself, DNA is biologically passed down.66 Just last year,
Joseph DeAngelo, also known as the “Golden State Killer,” was caught with
the assistance of triangulating his identity through the DNA of a familial
connection, a third cousin.67 Certain studies have found the availably of genetic testing data has made it such that one could potentially triangulate the
identities of a majority of individuals in the United States in the next few
year with the help of genetic information paired with additional personal in57.

See id.

58. Rosenbaum, supra note 8.
59. Jean-Christophe Bélisle Pipon et al., Genetic Testing, Insurance Discrimination
and Medical Research: What the United States Can Learn from Peer Countries, 25 NATURE MED. 1198, 1198–1204 (2019).
60.

See id.

61.

See id.

62.

See id.

63.

See id.

64.

See Rosenbaum, supra note 8.

65. Entrikin, supra note 13, at 785.
66.

Id. at 784.

67. JV Chamary, How Genetic Genealogy Helped Catch The Golden State Killer,
FORBES (June 30, 2020, 5:PM), https://www.forbes.com/sites/jvchamary/2020/
06/30/genetic-genealogy-golden-state-killer/?sh=27ce58e5a6d0 [https://
perma.cc/5XNM-KTMH].
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formation identifiers.68 This would not be an issue if people had consented to
their information being used or obtained.69 However, a familial connection
could be implicated by the actions of an individual without having personally
consented, as was the situation in DeAngelo’s situation.70 As a result of a
decision made by a familial connection, individuals without their consent
could have their information provided to pharmaceutical companies, used in
estate matters, tagged by law enforcement, or have personal health issues
known by others.71 Close biological relations face these risks simply by being
related to individuals who have provided information.72 At least one study
shows that over 75% of Americans are concerned with how companies and
the government use their personal data.73 It stands to reason that the use or
access to one’s data through a family member rather than through one’s own
actions would concern the populous even more.74
III.

LEGAL BACKGROUND/DEVELOPMENTS AND PROBLEMS

There have been numerous efforts at both the federal and state levels in
the United States to provide regulations for the genetics industry, or tangentially in the privacy sphere.75 A few proposals have been passed and many
have been, or are currently being, considered.76 Other countries around the
world, notably those in Europe, have also undertaken efforts to pass regulations or have considered steps to install regulations for the direct-to-consumer genetic testing field.77
A.

Federal Genetic Information Non-Discrimination Act (GINA)

The U.S. federal government’s first attempt at enacting regulation in the
genetics space was in 2008 with the passing of the Genetic Information Non68. Haag, supra note 34.
69. Entrikin, supra note 13, at 860.
70.

Id.; Chamary, supra note 67.

71.

See Entrikin, supra note 13, at 864.

72.

Id.

73. Auxier & Rainie, supra note 12.
74.

See Entrikin, supra note 13, at 860.

75.

See HHS, “GINA” THE GENETIC INFORMATION NONDISCRIMINATION ACT OF
2008 INFORMATION FOR RESEARCHERS AND HEALTH CARE PROFESSIONALS 1
(Apr. 6, 2009), https://www.genome.gov/sites/default/files/genomeold/pages/
PolicyEthics/GeneticDiscrimination/GINAInfoDoc.pdf [https://perma.cc/
DG38-PTW4] [hereinafter GINA].

76.

See id.

77. Ashleigh Furlong, Europe Eyes New Rules for ‘Wild West’ of DNA Testing,
POLITICO (Jan. 14, 2020, 1:25 PM), https://www.politico.eu/article/europeeyes-new-rules-for-wild-west-of-dna-testing/ [https://perma.cc/L2TM-PKAR].
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Discrimination Act (GINA).78 The bill passed almost unanimously in both
chambers of Congress and concluded a thirteen-year debate on the measure.79
First, GINA provides protection to individuals from health insurance providers from discrimination based on genetic information in both eligibility and
coverage decision making.80 This, however, applies only to health insurance
and does not regulate other forms of insurance.81 Second, genetic information
cannot be used discriminate in employment situations, such as in hiring and
promotion.82 This is similar to actions taken in the past to prevent discrimination in the workplace regarding other forms of health status.83 The regulation
explicitly places genetic information in the class of information that is not
allowed to be considered by employers or health insurer when making their
decisions.84 GINA also outlines numerous penalties for those companies that
seek to add genetic information as factor used in algorithms or decisionmaking processes.85 These penalties provide some teeth to the regulations
rather than just outlining illegality.86
Notably, GINA, while expansive in its regulations on most employers
and health insurers, leaves out numerous related industries that could readily
use genetic information.87 It specifically exempts employers with fewer than
15 employees.88 As another exception, companies providing insurance plans
including life, long-term care, disability, and types of property insurance that
could possibly use the information to discern riskier individuals and force
higher payments depending on the perceived risk are not impacted by
GINA.89 In this vein, it was argued, before passage, that GINA could force
higher payments for less-risky individuals when high-risk individuals cannot
be separated by their genetic information.90 This could materialize in individuals with specific genetic disorders inflating cost for the overall insurance
78. GINA, supra note 75, at 2.
79.

Id.

80. 29 U.S.C.A. § 1182(a)(1)(F) (2008).
81.

See id.

82. GINA, supra note 75, at 2.
83.

Id. at 1.

84.

Id. at 2.

85.

See 29 U.S.C.A. § 216 (2018).

86.

See id.

87.

See NIH, What is Genetic Discrimination?, MEDLINEPLUS (Jul. 28, 2021),
https://medlineplus.gov/genetics/understanding/testing/discrimination/ [https://
perma.cc/4HJ6-9S68].

88.

Id.

89.

Id.

90. Jessica D. Tenenbaum & Kenneth W. Goodwin, Beyond the Genetic Information Nondiscrimination Act: Ethical and Economic Implication of the Exclusion
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pool.91 With GINA, Congress drew a hard line with health insurance, but left
the door ajar in the other insurance spaces that may not be able to use genetic
information intelligently in their actuarial processes.92
B.

United States State Laws

Illinois has compiled some of the strictest genetics privacy laws.93 Notably, the laws require genetic testing entities to obtain written permission from
the test-taker before the results can be shared with any third party.94 The law
passed in 2009.95 The genesis of the law came from supporters who pushed
for a public policy update as the demands and use of genetic data grew.96
Utah passed its own Genetic Information Privacy Act in 2021 that is
specifically aimed at protecting consumers of direct-to-consumer genetic
testing products.97 The Act created requirements for companies to provide
notice, limit data usage, and require consent for usage of genetic data.98 Interestingly, the plan also required companies to provide a data security plan to
protect unauthorized use or access to the bank of genetic data held by the
company.99
Florida, in 2020, became the first state to extend genetic privacy testing
to all insurers, which is in addition to health insurers covered under the Federal GINA.100 Florida now prohibits insurers from using genetic information
of Disability, Long-Term Care and Life Insurance, 14(2) PER. MED. 153, 154
(2017).
91.

See id.

92.

See id. at 156.

93.

See 410 ILL. COMP. STAT. 513/15 (2021) (“Except as otherwise provided in this
Act, genetic testing and information derived from genetic testing is confidential
and privileged and may be released only to the individual tested and to persons
specifically authorized, in writing in accordance with Section 30, by that individual to receive the information”).

94.

Id.

95.

Id.

96. Sean Crawford, New Illinois Privacy Law For Genetic Test Results, NPR ILL.
(Dec. 30, 2019, 9:47 AM), https://www.nprillinois.org/health-harvest/2019-1230/new-illinois-privacy-law-for-genetic-test-results [https://perma.cc/XVP7C4H5].
97.

UTAH CODE ANN. §13-60-101 (West 2022).

98.

Id. §13-60-201 (West 2022).

99.

Id.; Julia K. Kadish, States Continue to Step in to Safeguard Genetic Information, XI 88 NAT’L L. REV., Mar. 29, 2021, at 2, https://www.natlawreview.com
/article/states-continue-to-step-to-safeguard-genetic-information [https://
perma.cc/LL3W-MWB4].

100. FLA. STAT. § 627.4301 (2020); Harry Valetk, Florida Becomes the First State
to Enact DNA Privacy Law Blocking Insurers from Genetic Data, BAKER MC-
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to create prices or offerings in the life insurance, disability insurance, and
long-term care insurance markets.101 Florida also updated its regulations in
2021 by making criminal penalties available for violations of state genetics
protection laws.102
In October of 2021, California added the Genetic Information Privacy
Act to the already-existing Consumer Privacy Act of 2018.103 This new Act
specifically applies to direct-to-consumer genetic testing companies.104 The
key provisions limits access to private data for third parties and institutes
procedures for the entire life-cycle of the genetics process.105 Further, the Act
also allows for customers to revoke consent in an action requiring destruction
of data within thirty days.106 Given this requirement, this law will likely set
the standard for state laws because of the wide ranging limits on the use of
genetic information by testing companies.107
Coming down the pipeline, the California Privacy Rights Act and the
Virginia Consumer Data Protection Act both passed in 2021 and are scheduled to go into effect soon.108 The laws mirror the current laws of the European Union under the General Data Protection Regulation, which is aimed at
data use widely rather than just genetics.109 Both Virginia and California laws
KENZIE (July 11, 2020), https://www.lexology.com/library/detail.aspx?g=66b
6b069-27dc-4fe3-91c3-17234ff5212e [https://perma.cc/M5UL-FT3A].
101. FLA. STAT. § 627.4301; Valetk, supra note 100.
102. Libbie Canter, Newly Effective Florida Law Imposing Criminal Sanctions Adds
to Developing Nationwide Patchwork of State Genetic Privacy Laws, COVINGTON (Oct. 6, 2021), https://www.insideprivacy.com/health-privacy/newly-effective-florida-law-imposing-criminal-sanctions-adds-to-developingnationwide-patchwork-of-state-genetic-privacy-laws/?utm_source=Mondaq
&utm_medium=Syndication&utm_campaign=ClinkedIn-integration [https://
perma.cc/5235-NWBU].
103. See Julia K. Kadish & Harrison Schafer, California Enacts New Privacy Law
for Genetic Data, XI 285 NAT’L L. REV., Oct. 12, 2021, at 2, https://
www.natlawreview.com/article/california-enacts-new-privacy-law-geneticdata#google_vignette [https://perma.cc/Z7VC-Q5K5].
104. Id.
105. See id. (“[P]rovide a customer with certain information regarding the company’s policies and procedures for the collection, use, maintenance, and disclosure, as applicable, of genetic data, and to obtain a consumer’s express consent
for collection, use, or disclosure of the consumer’s genetic data”).
106. Id.
107. See id.
108. Elizabeth Harding & Caitlin A. Smith, Virginia’s New Consumer Data Protection Act, XI 222 NAT’L L. REV., Aug. 10, 2021, at 2, https://www.natlawre
view.com/article/virginia-s-new-consumer-data-protection-act [https://
perma.cc/GQ93-EPR4].
109. Id.
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include genetic information on the list of data covered under the new rules
for a number of access, deletion, and control mechanisms that must be followed by businesses when personal data is in their possession.110 While not
as consequential for genetics regulation in California given the recent passage of the Genetics Information Privacy Act, this Act will serve as the basis
for most of the regulatory regime in Virginia.111
About half of the states in the U.S. have instituted regulations in the
areas of consent for either disclosure or performance of a genetic test.112 A
small number of states have gone as far as labeling genetic information as
personal property.113 Similar efforts have resulting in DNA samples being
labeled personal property, as personal rights slowly expand into the personal
genetics industry.114
Not all action, however, has been directed toward regulation. Oregon, in
the past twenty years, has eliminated the property right to DNA samples,
which demonstrates that despite momentum towards increased regulations,
there are still some locations moving in the opposite direction.115 Outside of
usage for personal or medical reasons, usage of genetic testing and genetic
information in the employment and the insurance industries, in particular, has
generated separate regulatory action.116 Similar to consent laws, these requirements or bans on the use of genetics to inform an employment or insurance decision are only present in a few states and are not uniform.117
C.

European Union Regulations

Like the structure of regulations in the U.S., European Union (EU) regulations come in the form of both overarching EU rules for all the member

110. Id.
111. Id.
112. State Genetic Privacy Laws, NAT’L CONF. OF STATE LEGIS. http://
pierce.wesleyancollege.edu/faculty/hboettger-tong/docs/hbt%20public%20
folder/FYS/State%20Genetic%20Summary%20Table%20on%20Privacy
%20Laws.htm [https://perma.cc/B9LL-7B2D] [hereinafter State Genetic]
(“Laws in 16 states require informed consent for a third party either to perform
or require a genetic test or to obtain genetic information. Twenty-four states
require informed consent to disclose genetic information. In addition, Rhode
Island and Washington require written authorization to disclose genetic
information”).
113. Id.
114. Id.
115. Id.
116. See id.
117. See State Genetic, supra note 112.

2022]

Direct-to-Consumer: Genetic Testing

365

states as well as country specific rules.118 The country-specific rules tend to
extend beyond the regulations set by the EU.119
In the EU, the General Data Protection Regulation dominates the regulatory regime for the member countries.120 Created in 2016 as an advancement
and update to the 1995 European rules, the regulations impose added controls
for individuals to dictate how their personal data is used.121 The goal was to
harmonize the member-countries’ laws, given the thicket that could emerge if
each country were to create its own set of regulations.122 Similar to the situation in the U.S., however, this left the door open for countries that desired to
enact their own national laws.123 The regulations impose added obligations
on controllers and processors of personal data but do little to force consent
for given services.124 These obligations require the data processors and handlers to prove their compliance with the law.125 The EU’s regulatory regime
has been described as one of toughest in the world.126 Fines could reach into
the tens of millions of Euros for violations.127 This is based on penalties of
upwards of 4% of a company’s global revenues, not profit, for violation just
in the EU, which will get the attention of any data handler.128
Adding on to the EU regulations, many European countries, including
France and Germany, have enacted country-specific regulatory schemes regarding personal data.129 The strictest regulation that currently exists is the
French ban on direct-to-consumer DNA testing.130 Currently, individuals
found guilty of breaking the French rules are liable for a _3,750 fine, which
makes France one of the few countries that creates criminal penalties for
users of direct-to-consumer DNA tests.131 The French bioethics rules are up118. Ben Wolford, What is GDPR, the EU’s New Data Protection Law?, EUR.
UNION, https://gdpr.eu/what-is-gdpr/ [https://perma.cc/T3CZ-43JZ].
119. See generally id.
120. Id.
121. Id.
122. See id.
123. See generally State Genetic, supra note 112.
124. Wolford, supra note 118.
125. Id.
126. Id.
127. Id.
128. Id.
129. See Eric Boodman, In France, It’s Illegal for Consumers to Order a DNA Spit
Kit. Activists Are Fighting Over the Ban, STAT (Nov. 14, 2019), https://
www.statnews.com/2019/11/14/france-consumer-genetic-testing-ban/ [https://
perma.cc/F534-NC36].
130. See id.
131. Id.
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dated every seven years, and sizeable pressure exists from industry groups to
lift or limit the restrictions; but as of now, the restrictions are still in place.132
France takes pride in having the strictest regulations of privacy with this
specific regulation concerning direct-to-consumer genetics.133 While strict,
the rules in France, including the fine or penalty, have never actually been
enforced, and consumers remain largely free to purchase the tests from companies outside the country.134 Germany’s legislation has similarly been considered as targeting direct-to-consumer genetic testing and limiting German
consumers’ access to this type of testing.135 Also, Germany is one of the few
countries to require post-test counseling to certain individuals based on the
test given.136
In other European countries, however, there are a less clear-cut lines as
to what is a medical test versus what is a recreational product because definitions differ among the countries.137 The regulations for genetic testing in
many countries are aimed at medical professionals but could encompass
some of the direct-to-consumer options depending on the specific regulations
of the country.138 Austria, Norway, and Portugal, for example, require written
consent for the completion of certain types of genetics tests.139 In Austria, genetic tests determining a manifested disease based on a germ line mutation, genetic tests determining predisposition to a disease (especially future
onset diseases or the determination of carrier status), and genetic tests for
prenatal diagnosis may only be performed upon written consent of the person
to be tested and after genetic counselling is complete.140 Informed consent
requires the individual indicate that they were informed in advance about the
genetic test’s nature, consequences, and significance.141 Portugal similarly restricts genetics testing without written consent for detecting heterozygosity
status of recessive diseases, diagnosing monogenic diseases, and testing for
genetic susceptibility in healthy individuals.142 These requirements vary by
country because they may depend on the type or the setting of the test
performed.143
132. Id.
133. See id.
134. Furlong, supra note 77.
135. Kalokairinou et al., supra note 17, at 126.
136. Id. at 124.
137. Id. at 129–30.
138. See id.
139. Id. at 126.
140. Id.
141. Kalokairinou et al., supra note 17, at 126.
142. Id.
143. See id. at 125.
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In Spain, written consent for testing is only required when performed in
a healthcare setting, thereby not including the direct-to-consumer option.144
In Norway, genetic counselling is compulsory when it comes to pre-symptomatic, predictive, and carrier tests.145 In Spain, counseling must be provided
for any health-related genetic testing.146 Further, in Spain, during genetic
counseling, an individual must be provided with adequate information regarding the consequences of genetic diagnoses and possible alternatives
available to the patient.147
Sweden is unique in that the requirements for genetic testing stipulate
that genetic testing must be accompanied by genetic counselling and informed consent from the patient.148 Further, professionals providing genetic
counselling must have specific training.149 Training certification, however,
does not appear difficult to obtain because, at present, there is neither university-level education in genetic counselling nor a requirement for professional
licensing or registration to be become a counselor.150 The penalties do not
appear to have been strictly enforced, but offer a unique hand-holding approach to genetic testing that could alter some people’s perception or understanding of the process before they begin.151 This requirement is much like
the requirement of pre-bankruptcy credit counseling in the United States for
consumer bankruptcy filers.152 The counselor, or process, has the potential to
impact how an individual approaches the process whether it be bankruptcy or
genetic testing.153
The Czech Republic acted in early 2017 by passing additional genetics
testing protocols.154 Specifically, the protocols established guidelines for the
quality of genetic services, prior information and consent, and genetic counselling.155 The protocols established a general rule on the conduct of genetic
144. Id. at 125.
145. Id. at 122.
146. Id.
147. Kalokairinou et al., supra note 17, at 122.
148. Rebecka Pestoff et al., Genetic Counsellors in Sweden: Their Role and Added
Value in the Clinical Setting, 24 EUR. J. OF HUM. GENETICS, 350, at 350
(2016).
149. Id.
150. Id.
151. See id.
152. 11 U.S.C. § 109(h).
153. See id.
154. Czech Republic Signs the Additional Protocol on Genetic Testing, COUNCIL OF
EUR. (Oct. 26, 2017), https://www.coe.int/en/web/bioethics/-/genetic-protocolsignature [https://perma.cc/A84Y-HN4P].
155. Id.
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tests, and was forward looking for the first time at the international level.156 It
delt with directly accessible genetic tests for which commercial offers could
develop (and obviously did within the next five years).157 Also, notably the
protocols established procedures for tests that could be carried out by people
who are unable to provide consent.158 Lastly, it dictated the protection of and
right to the information derived from the genetic testing.159
At the other end of the spectrum, numerous countries have no regulations for genetic testing, let alone direct-to-consumer testing.160 Countries
without regulations include Luxembourg, Poland, and Romania.161 While the
regulations implemented by the countries discussed above may look to provide some limitations, in actuality they may sit idle because direct-to-consumer genetic testing companies are based around the world and are not
subject to the regulations.162 As a result, even if a test is sent to a specific
European country, the regulation of this service may (or may not) fall outside
the national jurisdiction.163 Not to mention, the simple definition of what is in
the ‘practice of medicine’ varies by country, which furthers the non-uniformity of regulations across European nations.164
The varying actions of numerous European countries have created a
patchwork of regulatory actions much like the patchwork present in the
United States.165 These regulations provide differing sets of rules that must
be followed even as data, companies, and individuals increasingly travel
across country and state borders.166
D.

United States Federal Proposed Regulations

Not all proposals have sought to increase genetic regulation at the federal level in the United States.167 In 2017, a House resolution was introduced
that would have let employers demand access to their workers’ genetic test
results.168 This resolution did not pass, but it reflects the uncertain nature of
156. Id.
157. Id.
158. Id.
159. Id.
160. Kalokairinou et al., supra note 17, at 126.
161. Id.
162. Id. at 127.
163. Id.
164. Id.
165. See Kalokairinou et al., supra note 17, at 127.
166. See id.
167. See H.R. 1313 Rep. No. 115–459 (2017).
168. See id.
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changes to regulations in the genetics field and some of the possible push
back against regulations.169 Additionally, some free market tendencies may
seek to influence and chip away at the regulations in the future as well.170
In 2019, a House resolution was proposed for the enactment of the Genetic Information Privacy Act (GIPA).171 The resolution, if passed, would
have required commercial testing companies housing customers’ genetic data
to have express consent from consumers before the data could be used by
third parties.172 This Act would have given the Federal Trade Commission
(FTC) oversight of genetic data companies.173 Further, the Act would have
required that separate consent be provided for additional services and internal
testing.174 The resolution stalled and never made it out of the House.175 Regulation of direct-to-consumer genetics testing companies, however, could occur in the form of rulemaking from the FTC, the Centers for Medicare and
Medicaid Services, or the Food and Drug Administration.176
E.

Proposed Regulations in the United Kingdom

The United Kingdom (U.K.) does not follow the EU’s regulatory regime.177 Similar to other European countries, U.K.’s Parliament is now considering whether and what kind of regulation action is needed regarding
personal genetic information and privacy.178 Perhaps a positive sign is the
balancing of interests, both personal and business, being shown by Parliamentary members as possible advancements in science are weighed against
personal protections.179 New rules being considered seek to add some teeth,
given that the current set of regulations lack any consequences for individu169. See Ricki Lewis, Saving GINA: Is Genetic Privacy Imperiled?, PLOS BLOG
(Mar. 9, 2017), https://dnascience.plos.org/2017/03/09/saving-gina-is-geneticprivacy-imperiled/ [https://perma.cc/M522-XYRU].
170. Id.
171. Genetic Information Privacy Act of 2019, H.R. 2155, 116th Cong. §1 (2019).
172. Id. at § 2(a)(1)(a).
173. Id. at § 3(a)(2).
174. Id. at § 2(a)(2).
175. Id.
176. CONTRERAS & DESHMUKH, supra note 22, ch. 13 at 12.
177. See MPs Urge Government to Review Regulations for Direct-to-Consumer Genetic Testing, UK PARLIAMENT (Jun. 22, 2021), https://committees.parliament.uk/committee/135/science-and-technology-committee/news/
156039/mps-urge-government-to-review-regulations-for-directtoconsumer-genetic-testing/ [https://perma.cc/Q544-CUMR] [hereinafter MPs Urge Government]; SCI. & TECH. COMMITTEE, REPORT, 2021-2, HC 94, ¶ 13 (UK).
178. See MPs Urge Government, supra note 177.
179. See id. 77.

370

SMU Science and Technology Law Review

[Vol. XXV

als and businesses breaking genetic testing regulations.180 This will likely
layer on current regulations in the U.K. that are modeled after regulations of
other European countries and distinguish between medical providers and direct-to-consumer options.181 Currently, U.K. regulations do not prohibit the
sale or use of direct-to-consumer offerings.182
F.

U.S. State Proposed Regulations

Interestingly, the state of California proposed genetic privacy legislation
that passed in 2021, mentioned earlier in the comment, was earlier vetoed by
Governor Newsom in 2020.183 The regulations, called the Genetic Information Privacy Act, require informed consent before disclosing data to third
parties.184 While the California bill was pending, Governor Newsom vetoed
the bill because he thought it would hurt the response to the COVID-19 pandemic.185 In response to California’s proposed regulation, other states, such
as Arizona, considered whether to should pass more restrictive legislation.186
More U.S. citizens have been using direct-to-consumer options—in fact, in
2021, 20% of the United States population were estimated to have used an at
home genetic test.187 As a growing population uses these options, it stands to
reason that more states will consider adding regulations because many of the
efforts in Congress have stalled.188
IV.

THE IMPLICATIONS OF CURRENT & PROPOSED
REGULATION

Currently, the United States federal regulations create a minimum standard for regulatory action in the genetics space, but state action has the opportunity to go further.189 Though limited to health insurance and
180. Furlong, supra note 77.
181. Kalokairinou et al., supra note 17, at 127.
182. Id.
183. Alyssa M. Sones, California Governor Pulls the Plug on Genetic Information
Privacy Act, X 294 NAT’L L. REV., Oct. 20, 2020, at 1, https://
www.natlawreview.com/article/california-governor-pulls-plug-genetic-information-privacy-act [https://perma.cc/XT8X-KCDE].
184. Id.
185. Id.
186. Emily Mullin, States Are Toughening Up Privacy Laws for At-Home DNA
Tests, WIRED, (Oct. 21, 2021, 9:00 AM), https://www.wired.com/story/statesare-toughening-up-privacy-laws-for-at-home-dna-tests/ [https://perma.cc/
5PDY-QU2K].
187. Id.
188. See id.
189. See GINA, supra note 75, at 1.
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employment scenarios, the GINA regulations of 2008 provide the current
basis for nation-wide regulatory activity in the United States.190 The patchwork of regulations by states provide a view into the possible regulations that
could be implemented nation-wide as well as the impact that specific regulation has on privacy in the genetics industry.191 This contrasts the regulatory
regime in Europe, which mostly focuses on regulating the framework within
which the genetic tests are provided but then leaves issues related to appropriate medical supervision, genetic counselling, and adequate informed consent processes unregulated.192
Overall, consumers and companies in the genetic testing space face numerous potential privacy issues. Given the traditional informed consent requirement of contract law, most companies have indemnity provisions in
their contracts that waive all consumer rights to later bring suit for invasion
of privacy or other claims.193 On its face, the numerous iterations of regulations that contemplate mandatory disclosure requirements would limit the
ability of companies to use this method to avoid liability and allow for genetic data use.194 Mandatory disclosure for gene testing has been passed in
Illinois and proposed at the federal level and in other states.195 However,
there is limited applicability to some of the regulations for the full-array of
uses for genetic information.196
The 2008 federal regulation GINA limited the use of genetic information in employment and health insurance situations.197 The Act was structured to increase public confidence in the Human Genome Project as well as
the increase in genetic research in the healthcare arena.198 When GINA was
passed, many regulators anticipated that the patchwork of state regulations
would be eliminated by the introduction of a consistent federal regulatory
structure.199 Now thirteen years later, the patchwork of state regulations for
genetic information has remained, and numerous states have added more reg-

190. Id.
191. See id.
192. Kalokairinou et al., supra note 17, at 119.
193. See Entrikin, supra note 13, at 863.
194. E.g., 410 ILL. COMP. STAT. 513/15 (1997).
195. Id.
196. Valetk, supra note 100; See FLA. STAT. § 627.4301 (2020).
197. GINA, supra note 75, at 1.
198. Id.
199. Stephen E. Trimboli & Marissa B. Ruggiero, Navigating the Genetic Information Nondiscrimination Act of 2008, 58 FEDR. LAW. 24, 26 (Nov./Dec. 2011)
(“Prior to enactment of GINA, 34 states and the District of Columbia had
promulgated their own genetic discrimination laws”).
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ulations to the minimum requirements created by GINA.200 Genetic information can now theoretically be useful in a number of other closely related
insurance businesses, as discussed above, and in medical development.201
Use of genetic information has advanced well beyond simple genetic
testing to new uses that threaten one’s personal privacy.202 Genetics data allows police and detectives to match or partially match DNA to cold cases
using DNA from even distant biologic relatives, which, in turn, threatens
personal privacy.203 Commercial entities have long had incentives to get access to data but now so does law enforcement.204 Multiple consumer genetics
testing companies claim to take privacy seriously, yet their contracts contain
clauses allowing disclosure of information to the government or other third
parties as they see fit.205
There is also a concern for hacking, or the stealing of, genetic data that
is similar to concerns with personal health or credit card information.206
States that have enacted regulations around the proper storage of personal
information are at the forefront of alleviating some of the concerns.207 However, genetic information is sometimes forgotten by consumers and not
tracked as rigorously as credit reports.208 Regulation for proper storage of
genetic information can also add a burden to businesses.209 No efforts are
perfect, but with the rise in data breaches, many states seem to be looking at
ramping up standards in an effort to make these data breach events less severe and less frequent.210
The concern of law enforcement access to genetic data is separate from
concerns of private companies selling or providing genetic data for research

200. See Valetk, supra note 100.
201. Id.
202. Entrikin, supra note 13, at 781; See Stein, supra note 15.
203. See Stein, supra note 15, (referencing quote by Yaniv Erlich: “It is kind of like
each person in this database is a beacon that illuminates hundreds of distant
relatives”).
204. Entrikin, supra note 13, at 784–85.
205. See Rosenbaum, supra note 8.
206. Id.
207. Id.
208. See id.
209. See UTAH CODE ANN. § 13-60-201 (2021); see Kadish, supra note 99.
210. See Consumer Bob & Nicholas Kjeldgaard, Data Breaches Could Reach AllTime High by End of 2021: ITRC, NBC SAN DIEGO (July 15, 2021, 7:52 PM),
https://www.nbcsandiego.com/news/investigations/nbc-7-responds/databreaches-could-reach-all-time-high-by-end-of-2021/2655793/ [https://
perma.cc/UW6J-S6BZ].
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or other purposes.211 While some companies clearly obtain an individual’s
consent to be included in third party research, other companies allow their
contracts to establish the right to freely distribute collected data to other parties as they see fit.212 There is the additional question of what constitutes a
company asset in the event of a company being acquired at a later date.213
Various outcomes present regulators and the public with the question of
whether there should be a leash on personal genetic data, and if so, then what
action is best. The current regulations, or proposed regulations, seem to
mostly limit uses in a discriminatory sense and place barriers to mandatory
disclosure requirements.214
For biologic relations, there has been little attention paid by regulators
outside of law enforcement access to familial DNA.215 Compared to individuals that provide the DNA sample, even with mandatory disclosure requirements, there is little oversight or control on how that information is used
regarding biological relatives.216 Furthermore, one may not be aware that a
biological relative provided a genetic sample to a company, which may then
use the information.217 An individual’s privacy could be compromised based
on the disclosure of a relative to any direct-to-consumer testing company.218
Mandatory disclosure requirements of any data use does limit how easily
data can be disseminated, but genetics forms an unique problem because the
information cannot be “put back in the bottle” after the data has left the
original testing company.219 Unlike changing a number or password to protect your identity or credit card, genes can never be changed, and they may
be unretrievable once released.220 Even if it was required to notify someone
of usage or testing, there is no easy way to regulate, track, or ensure these
steps have been followed.221 Biologic relations have the same concerns about
211. Eric Rosenbaum, Genetic Testing Company 23andMe Rises in First Trade After Richard Branson SPAC Merger, CNBC (June 17, 2021, 12:47 PM), https://
www.cnbc.com/2021/06/17/gene-testing-firm-23andme-trades-higher-afterbranson-spac-merger-.html [https://perma.cc/QB5L-B4EJ].
212. See id.; Stephen Gandel, Private Equity Wants to Own Your DNA, CBS NEWS
(Aug. 7, 2020, 4:52 PM), https://www.cbsnews.com/news/blackstone-privateequity-ancestry-com-dna/ [https://perma.cc/7APH-5MQG].
213. See Gandel, supra note 212 (providing an example of information provided by
DNA tests being part of a company’s assets).
214. E.g., UTAH CODE ANN. § 13-58-201 (2021).
215. See Stein, supra note 15.
216. See id.
217. Id.
218. Id.
219. Id.
220. See id.
221. See Entrikin, supra note 13, at 857; see Stein, supra note 15.
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security as the individual who provided their genetic data to direct-to-consumer entity.222 As a bystander to any transaction, currently regulations do
not considered the effect on biologic relations. As such, companies are, in a
sense, morally trusted to preserve the rights of consumers without any regulatory guidance of their actions.
V.

PROPER REGULATORY ACTION GIVEN THE IMPACT OF
REGULATIONS

The varying impact of regulatory standards strains the relationship between individual privacy rights, data rights, and potential medical progress.223 A data sharing model or framework could potentially offer a middle
ground that would prevent individual countries from bogging down the sharing of data, while also protecting the public from unscrupulous data sharing
or selling.224 Proposals out of Europe discuss a code of conduct that would
allow for better international transfers of data between countries that use similar models by providing a common standard to follow and allow for countries to simply add themselves to the network in the future.225 Europe has
slowly implemented uniform standards for certain aspects of medical services or products.226 One example is the implementation of the 2017 Regulation on in vitro diagnostic (IVD) medical devices, which created a blanket
limitation on tests using these medical devices.227 Because of the limitations
placed on IVDs used for medical services in clinical settings, there were critics who felt this was an intrusion on medical providers in certain countries.228
In regard to direct-to-consumer genetic test offerings, however, critics of the
limitation can be subdued with the knowledge that only the testing companies, and not clinical providers, would be subject to the new regulations.229
Regulations should be as clear as possible because interpretive questions
tend to create more problems than solutions and should be avoided especially
when millions of dollars in fines are possible.230 From a business perspective,
regulations that can eliminate uncertainty, while maintaining the integrity of
the standards, are best. The most obvious way to address this within the ex222. Entrikin, supra note 13, at 857.
223. See Kalokairinou et al., supra note 17, at 128.
224. See Entrikin, supra note 13, at 895.
225. See Kalokairinou et al., supra note 17, at 120.
226. See id.
227. Id.
228. Id.
229. See id. at 129.
230. See European Society of Human Genetics Critiques EU’s GDPR, SCI. ADVISORY BD. (Aug.30, 2021), https://www.scienceboard.net/index.aspx?sec=
Srr&sub=def&pag=dis&ItemID=3211 [https://perma.cc/D5UT-7K4A] [hereinafter Critiques].
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isting “ecosystems” of Europe or the United States is through collaboration
between member countries or states to facilitate uniform partnerships and
enforcement of the rules rather than a patchwork of regulations.231 This will
allow for the sharing of information, and when there is a more uniform basis
from which to operate, for businesses to succeed.232
The use of genetic data by third parties can cause issues, but the key
choice regulators can make is a distinction between using the data with or
without personal identifiers.233 As was previously noted, privacy concerns
exist regarding government and businesses access to consumer’s personal
data.234 When the ability to separate personal identifiers from the data becomes available, a compromise between data privacy and scientific advancement can be reached by protecting consumers through hiding their personal
identification, while simultaneously allowing for commercial and medical
advancement through data sharing.235 This will balance the ability of gains
possible from the data without the issues of personal connection to the samples provided by consumers.236 Another potential benefit of separating personal information from genetic data is that after the first consented use, law
enforcement or government requests to use the data can be limited due to the
fact that personal identifiers have been eliminated and cannot be readily
given to the government.237 Thus, the traditional channels of an individual’s
consent or a court order would be the only ways for law enforcement to
acquire genetic data.
Finally, the biggest issue regarding personally identified genetic data is
that it cannot be altered.238 Use of genetic data against an individual creates a
policy issue of potential fairness.239 Some states have outlawed the usage of
genetic data for employment or certain insurance coverage, but the laws are
nowhere near uniform.240 The use of genetic data, when linked to one’s identity, should require consent and should not be allowed for any additional use
later on without additional consent by the individual who provided the genetic data. The new California regulation that requires that a direct-to-consumer company destroy the data sample within thirty days after receiving a
notification of revoked consent by the sample provider is an interesting way
231. See id.; Trimboli & Ruggiero, supra note 199, at 26.
232. See Citiques, supra note 230; see Trimboli & Ruggiero, supra note 199, at 26.
233. Entrikin, supra note 13, at 857.
234. Auxier & Rainie, supra note 12.
235. See Entrikin, supra note 13, at 892, 896.
236. See id.
237. See id. at 785 n.5.
238. See id. at 892.
239. E.g., Stein, supra note 15.
240. See Valetk, supra note 100.
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to keep control of personal data.241 This is a great way for consumers to
potentially reel in their past decision to participate in a testing service.242 The
goal is balance, allowing for innovation and protecting the public from the
risk of being taken advantage of by a testing service.243 Another path to
achieve this balance would be to require genetic test providers to gain consent for all their uses of the data through contracts with individuals.244
From an enforcement perspective, penalties that include a civil penalty,
class actions, or the loss of the right to practice could be a solid basis for
enforcement. There is also a potential for disgorgement or, like the EU, for
allowing damages as high as 4% of revenue.245 All of this can be implemented to deter companies from breaking the law.
Solutions do not exist only in the regulatory or political sphere. From a
business perspective, businesses need to evaluate potential regulations and
the varied regulations that exist around the world.246 Businesses have a
chance to direct and implement processes that guide the regulations of the
future.247 All direct-to-consumer options have a brand as wells as an image
that is earned over time through the businesses’ processes and actions.248
From a brand perspective, businesses can identify different legislative tools
that may be useful in guiding direct-to-consumer genetic testing companies
to act responsibly, and can give the public confidence in certain regulatory
rules or standards.249 Additionally, businesses have a chance to protect themselves from liability by not pushing the limits of what is acceptable, but instead keeping and meeting customer expectations for service, privacy, and
data protection.250 Depending on how they choose to do business, businesses
can have a huge impact on hindering or assisting with the creation of
regulations.251
Finally, to protect biologic relations, the regulatory options seem to emanate best from effective policies regarding individual genetic privacy. As
noted, studies have found the availability of genetic testing data in the United
States has made it so that one could potentially triangulate the identities of a
241. See Kadish & Schafer, supra note 103, at 2.
242. See id.
243. Entikin, supra note 13, at 860, 865.
244. See Kadish & Schafer, supra note 103, at 2.
245. See Wolford, supra note 118.
246. See id.
247. Entikin, supra note 13, at 866.
248. See Rosenbaum, supra note 8.
249. See Entikin, supra note 13, at 866.
250. See Rosenbaum, supra note 8.
251. See Kalokairinou et al., supra note 17, at 130.
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majority of individuals in the United States in the next few years.252 Clamping down on data from genetic tests means that fewer individuals who did not
submit their genes for testing would be caught up in a close relative’s personal data.253 By limiting the dissemination of personal genetic information
in general the privacy concerns for biological relatives decrease
significantly.254
Overall, a uniform set of regulations has the most potential to limit the
disparate impact that the current patchwork of regulations has on businesses.
By preempting state rules, a federal set of laws could eliminate the thicket of
rules while also allowing regulations to be more easily enforced. Should Europe achieve uniformity before the United States, its rules could offer a
framework or model for the United States to emulate. Finally, when personal
identifiers can be eliminated a middle ground could potentially allow for the
use of genetic data for medical advancement without compromising concerns
over privacy.
VI.

CONCLUSION

The genetics industry and its impact on human life continue to grow. As
such, the issues of privacy and protection of information that can be culled
from individual genes or the human genome grow as well. The current federal regulation in the United States creates a nation-wide minimum standard,
but variations in state requirements create a confusing patchwork of regulations. Additionally, there are concerns from a commercial and privacy aspect,
as globally the world lacks a common approach. Numerous questions linger
on how genetic data should, or can, be treated. Congress seems inclined not
to preempt state laws on privacy and genetics. As such, the patchwork of
state regulations seems here to stay. On a related note, there is uncertainty on
how the genetic data is used after testing and whether companies may provide the data to third parties. Moreover, there is little to no thought on how
genetic data voluntarily obtained by one individual can be used in regard to
individuals who share a genetic relationship. Close biological relatives share
a high percentage of the identical genes but may not have consented to provide genetic data. Europe offers another basis for ideas on how to regulate
the direct-to-consumer genetics industry. They have a General Data Protection Regulation for the entire European Union, but individual countries have
added regulation well beyond those provided by the European Union. Considering the impacts of genomics on closely related individuals ushers in new
questions on how to properly regulate the genomics industry.
From a proposed regulatory regime perspective, it is best to try and preempt individual states or country regulations. First, though perhaps unattainable, this proposed uniformity in a regulatory regime would aid in the
252. Haag, supra note 34.
253. See Entrikin, supra note 13, at 860.
254. See id.
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enforcement of and the conformity to the rules, and, perhaps most importantly, aid in the ability for cross-border data sharing and medical advancements. Next, this proposed uniform regulatory regime would create the
ability to consider a middle ground for data sharing when personal identification is made unavailable. This “faceless” data could be used for commercial
and medical advancement without the worries associated with personal privacy. Finally, the ability of companies to use personally identified data
should at a minimum mandate informed consent for additional use from the
consumer, and consent should perhaps not be allowed at all given the potential of violations to personal privacy. Regulators have been mostly passive,
but opportunities to harmonize the rules exist within the European Union and
the United States to both further the advancement of science and data usage,
while protecting individual privacy.

